A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.
Lancet HIV
; 1(2): e60-e67, 2014 Nov 01.
Article
in En
| MEDLINE
| ID: mdl-26366430
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Lancet HIV
Year:
2014
Type:
Article